Tags : Pericarditis

Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the

Tuba Khan March 19, 2021

Shots: The approval is based on the P-III RHAPSODY trial involves assessing Arcalyst (SC, qw, 300mg followed by 160mg) vs PBO in adults and children aged ≥12yrs. in a ratio […]readmore

Regulatory

Kiniksa’s Rilonacept Receives the US FDA’s Orphan Drug Designation to

Tuba Khan July 17, 2020

Shots: The US FDA has granted ODD for Kiniksa’s Rilonacept to treat pericarditis, which includes recurrent pericarditis. The company plans to submit sBLA in recurrent pericarditis to the US FDA […]readmore

Tags : Pericarditis

Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the

Kiniksa’s Rilonacept Receives the US FDA’s Orphan Drug Designation to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Pericarditis

Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the

Kiniksa’s Rilonacept Receives the US FDA’s Orphan Drug Designation to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company